Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要旨
エスラックス®(MSD,先発品)の後発医薬品であるロクロニウム臭化物静注液「マルイシ」(丸石製薬,後発品)は,先発品と同様の薬効が見込まれているが,それを裏付けるデータはない。今回,後発品の作用発現時間を調査し,先発品の治験データと比較検討した。後発品調査は,先発品の治験と同様に対象患者を定め,データを取得した。
後発品の作用発現時間は,先発品と比較し0.6mg・kg−1群で長かった(84.6±29.5秒 vs 146.0±71.3秒,P<0.001)が,0.9mg・kg−1群では有意差はなかった(77.1±27.5秒 vs 90.5±28.9秒,P=0.071)。
The generic drug Maruishi®, which is a rocuronium bromide intravenous solution, is expected to have the same efficacy as Eslax®, but no data have yet been presented to support this. In this study, the onset time of action of Maruishi® was investigated and compared with that in the clinical trial data of Eslax®. The methods used were the same as those used in the clinical trial for the original drug, including the patient inclusion and exclusion criteria. The onset of action of the generic drug was longer than that of the original drug when 0.6 mg・kg−1 was used(P<0.001), but there was no significant difference when 0.9 mg・kg−1 was used.
Copyright © 2024 KOKUSEIDO CO., LTD. All Rights Reserved.